CEACAM5 and colorectal carcinoma: For example, 111In-labeled ZCE-025 (an anti-CEA mAb that does not react with normal granulocyte glycoproteins) was investigated in several studies for the detection of primary, metastatic, or recurrent colorectal carcinomas (Abdel-Nabi et al. 1988; Abdel-Nabi et al. 1991; Kramer et al. 1988; Patt et al. 1988; Patt et al. 1990).